share_log

藥明合聯：截至2024年4月30日止股份發行人的證券變動月報表

WUXI XDC: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2024

Hong Kong Stock Exchange ·  May 6 17:07
Summary by Futu AI
藥明合聯生物技術有限公司（WuXi XDC Cayman Inc.），股份代號02268，於2024年5月6日向香港交易及結算所有限公司提交了最新的證券變動月報表。報告顯示，截至2024年4月30日，公司的法定/註冊股本結存維持在10,000,000,000股，每股面值0.00005美元，總額500,000美元，本月無增減變動。此外，公司的股份期權計劃下，包括2021年及2023年首次公開發售前購股權計劃，本月內無新股份因行使股份期權而發行，且無購股權於上市當日或之後授出。執行董事、首席財務官兼公司秘書席曉捷確認，所有證券發行均已獲董事會授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
藥明合聯生物技術有限公司（WuXi XDC Cayman Inc.），股份代號02268，於2024年5月6日向香港交易及結算所有限公司提交了最新的證券變動月報表。報告顯示，截至2024年4月30日，公司的法定/註冊股本結存維持在10,000,000,000股，每股面值0.00005美元，總額500,000美元，本月無增減變動。此外，公司的股份期權計劃下，包括2021年及2023年首次公開發售前購股權計劃，本月內無新股份因行使股份期權而發行，且無購股權於上市當日或之後授出。執行董事、首席財務官兼公司秘書席曉捷確認，所有證券發行均已獲董事會授權，並符合香港聯合交易所有限公司證券上市規則的相關要求。
Pharmaceutical United Biotechnology Co., Ltd. (WuXi XDC Cayman Inc.) , share code 02268, filed an updated monthly statement of changes in securities with Hong Kong Trading and Settlement Limited on 6 May 2024. The report shows that as of April 30, 2024, the company's regulated/registered share capital remained at 10,000,000,000 shares with a face value of $0.00005 per share for a total of $500,000, unchanged this month. In addition, under the Company's stock option plan, including the 2021 and 2023 Initial Public Offering Share Option Plans, no new shares were issued during this month as a result of the exercise of share options and no share rights were granted on or after the listing date. The Executive Director, Chief Financial Officer and Company Secretary Shi Xiaojie confirmed that all securities issuance has been authorised by the Board of Directors and complies with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Pharmaceutical United Biotechnology Co., Ltd. (WuXi XDC Cayman Inc.) , share code 02268, filed an updated monthly statement of changes in securities with Hong Kong Trading and Settlement Limited on 6 May 2024. The report shows that as of April 30, 2024, the company's regulated/registered share capital remained at 10,000,000,000 shares with a face value of $0.00005 per share for a total of $500,000, unchanged this month. In addition, under the Company's stock option plan, including the 2021 and 2023 Initial Public Offering Share Option Plans, no new shares were issued during this month as a result of the exercise of share options and no share rights were granted on or after the listing date. The Executive Director, Chief Financial Officer and Company Secretary Shi Xiaojie confirmed that all securities issuance has been authorised by the Board of Directors and complies with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.